Infanrix-IPV/Hib

BIOLOGICAL5 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BInfections, StreptococcalPertussisPoliomyelitisTetanus

Phase 3

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

CompletedNCT00808444

GlaxoSmithKlineInfections, Streptococcal

Start: 2009-01-05End: 2009-11-02Updated: 2018-08-17

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

CompletedNCT01119625

GlaxoSmithKlineInfections, Streptococcal

Start: 2010-07-12End: 2011-02-17Updated: 2018-09-20

A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia

CompletedNCT02858440

GlaxoSmithKlineDiphtheria, Haemophilus Influenzae Type b, Hepatitis B +2

Start: 2016-09-13End: 2018-11-13Updated: 2019-09-24

Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants

WithdrawnNCT03128489

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +2

Start: 2017-12-01End: 2018-08-01Updated: 2017-12-26

Phase 4

Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment

CompletedNCT01235949

GlaxoSmithKlineInfections, Streptococcal

Start: 2010-11-12End: 2012-12-08Updated: 2019-05-10

Related Papers

Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

Human Vaccines & Immunotherapeutics2020-02-126 citations

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable<i>Haemophilus influenzae</i>protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial

Human Vaccines & Immunotherapeutics2016-08-1923 citations

A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia

BMC Infectious Diseases2014-10-026 citations